333. ハッチンソン・ギルフォード症候群 [臨床試験数:5,薬物数:5(DrugBank:3),標的遺伝子数:4,標的パスウェイ数:6]
Searched query = "Hutchinson Gilford syndrome", "Hutchinson Gilford progeria syndrome", "HGPS"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03895528 | August 2019 | 29 July 2019 | Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy | A Treatment IND (Investigational New Drug) Protocol for EAP (Expanded Access Program) for the Use of Lonafarnib in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) or Progeroid Laminopathy | Progeria;HGPS | Drug: Lonafarnib | Eiger BioPharmaceuticals | Not recruiting | 12 Months | N/A | All | Phase 3 | |||
2 | NCT03871972 | March 5, 2019 | 6 May 2019 | Umbilical Cord Blood Transfusion in Progeria Syndrome | Safety and Efficacy of Umbilical Cord Blood Transfusion in Patients With Hutchinson-Gilford Progeria Syndrome | Hutchinson-Gilford Progeria Syndrome | Drug: Umbilical Cord Blood Unit | Bundang CHA Hospital | Recruiting | N/A | N/A | All | 2 | Phase 1/Phase 2 | Korea, Republic of | |
3 | NCT00916747 | August 2009 | 24 June 2019 | Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria | An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid Laminopathies | Progeria | Drug: Lonafarnib, Zoledronic Acid, and Pravastatin | Boston Children’s Hospital | Schering-Plough;Merck Sharp & Dohme Corp. | Recruiting | N/A | N/A | All | 85 | Phase 2 | United States |
4 | NCT00879034 | March 2009 | 24 June 2019 | A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria | A Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies | Progeria;Hutchinson-Gilford Syndrome | Drug: Lonafarnib;Drug: Zoledronic Acid;Drug: Pravastatin | Boston Children’s Hospital | Dana-Farber Cancer Institute;Brigham and Women's Hospital;Schering-Plough | Not recruiting | N/A | N/A | All | 5 | Phase 2 | United States |
5 | NCT00425607 | May 2007 | 11 June 2018 | Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria | An Open Label Dose Adjusted Phase II Trial of the Oral Farnesyltransferase Inhibitor (FTI) Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies | Progeria;Hutchinson-Gilford Syndrome | Drug: Lonafarnib | Monica E. Kleinman | Schering-Plough | Not recruiting | 1 Year | N/A | All | 29 | Phase 2 | United States |